| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Study of SDX in Patients With Idiopathic Hypersomnia (IH)NCT05668754 | Zevra Therapeutics | Phase 2 | Completed | 2024-02-28Actual |
| Study of TTI-101 in Participants With Idiopathic Pulmonary FibrosisNCT05671835 | Tvardi Therapeutics, Incorporated | Phase 2 | Completed | 2025-08-14Actual |
| AMX0035 in Adult Patients With Wolfram SyndromeNCT05676034 | AMLX | Phase 2 | Active not recruiting | 2024-07-23Actual |
| Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaNCT05678673 | Exelixis | Phase 3 | Active not recruiting | 2026-12-15Estimated |
| A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic MigraineNCT05679908 | Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | 2023-10-08Actual |
| CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)NCT05681351 | IONS | Phase 3 | Active not recruiting | 2027-03Estimated |
| A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate ADNCT05686044 | ANVS | Phase 2, Phase 3 | Completed | 2024-02-13Actual |
| Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)NCT05686408 | Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | 2023-09-29Actual |
| AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)NCT05693142 | RGNX | Phase 2, Phase 3 | Active not recruiting | 2026-09Estimated |
| A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With DermatomyositisNCT05695950 | LKFT | Phase 2 | Completed | 2025-10-13Actual |
| Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationNCT05696626 | LeonaBio | Phase 3 | Recruiting | 2027-04Estimated |
| Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System AtrophyNCT05696717 | Theravance Biopharma | Phase 3 | Active not recruiting | 2026-01Estimated |
| A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney DiseaseNCT05709444 | PTN | Phase 2 | Completed | 2024-04-26Actual |
| Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDNCT05711940 | COMPASS Pathways | Phase 3 | Active not recruiting | 2025-11-13Actual |
| Phase 2b Study of ALTO-100 in MDDNCT05712187 | Alto Neuroscience | Phase 2 | Completed | 2024-09-05Actual |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsNCT05712356 | LSTA | Phase 2 | Completed | 2026-04-05Actual |
| Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)NCT05712694 | Polaris Group | Phase 3 | Terminated | 2026-05-25Actual |
| Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell TherapyNCT05714345 | Allogene Therapeutics | Phase 2 | Terminated | 2024-02-20Actual |
| A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)NCT05716100 | XENE | Phase 3 | Recruiting | 2028-01Estimated |
| A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)NCT05717920 | ALDX | Phase 2 | Completed | 2023-11-21Actual |
| An Open-label Study of XEN1101 in EpilepsyNCT05718817 | XENE | Phase 3 | Enrolling by invitation | 2033-04Estimated |
| Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose ExcursionsNCT05721729 | VOGX | Phase 2 | Completed | 2024-05-01Actual |
| A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated PatientsNCT05725018 | ABEO | Phase 3 | Active not recruiting | 2025-09-30Estimated |
| Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.NCT05727904 | IOVA | Phase 3 | Recruiting | 2028-03-01Estimated |
| Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)NCT05731544 | BMEA | Phase 1, Phase 2 | Completed | 2024-11-18Actual |
| A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderNCT05733546 | COMPASS Pathways | Phase 2 | Active not recruiting | 2025-09Estimated |
| Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCNCT05733598 | Replimune, Inc. | Phase 2 | Recruiting | 2027-12-01Estimated |
| RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCNCT05733611 | Replimune, Inc. | Phase 2 | Terminated | 2025-08-18Actual |
| To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-MNCT05733780 | Bioxytran Inc. | Phase 2 | Unknown | 2023-12Estimated |
| Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque PsoriasisNCT05739435 | ALMS | Phase 2 | Active not recruiting | 2027-12-01Estimated |
Trial details
- Registry ID
- NCT05668754
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05671835
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05676034
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05678673
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05679908
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05681351
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05686044
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05686408
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05693142
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05695950
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05696626
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05696717
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05709444
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05711940
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05712187
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05712356
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05712694
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05714345
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05716100
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05717920
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05718817
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05721729
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05725018
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05727904
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05731544
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT05733546
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05733598
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05733611
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05733780
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05739435
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.